Recombinant HSP27 can be combined with antibodies targeting the angiotensin II type 1 (AT1) receptor to form a ZZ-TAT-GFP fusion protein that specifically targets cardiomyocytes, and can reduce apoptosis, reduce the area of myocardial fibrosis, increase ejection fraction, reduce end-systolic volume and end-diastolic pressure, and improve cardiac function after MI (90). The gene discussed is HSPB1; the disease is myocardial infarction.